(CLRB) |
| 0 (0%) 09-17 12:52 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 2.70 |
| Resistance 1: | 2.54 |
| Pivot price: | 2.40 |
| Support 1: | 2.29 |
| Support 2: | 1.91 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | -2.210 |
| Book Value | 3.620 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -58.4 |
| Return on Equity (ttm) | -119.6 |
Company news
Fri, 11 Sep 2026
CLRB Stock Surged 27% Today – Here’s Why Retail Is Bullish About Cellectar’s Blood Cancer Trial Data - Stocktwits
Thu, 20 Aug 2026
Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript - The Globe and Mail
Tue, 18 Aug 2026
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy - Slideshow (NASDAQ:CLRB) 2026-08-18 - Seeking Alpha
Fri, 14 Aug 2026
Cellectar Biosciences (CLRB) investor discloses 9.99% stake and warrant holdings - Stock Titan
Thu, 13 Aug 2026
Cellectar Reports $6.9 Million Second-Quarter Net Loss as Phase 3 Preparation Begins - Quiver Quantitative
Sat, 11 Jul 2026
Cellectar Biosciences (CLRB) Stock Fair Value Moves Lower As Analysts Weigh Execution Risk - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
